A carregar...
Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4928781/ https://ncbi.nlm.nih.gov/pubmed/27362533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0157957 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|